These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 19345579)

  • 21. Discovery and SAR of benzyl phenyl ethers as inhibitors of bacterial phenylalanyl-tRNA synthetase.
    Montgomery JI; Toogood PL; Hutchings KM; Liu J; Narasimhan L; Braden T; Dermyer MR; Kulynych AD; Smith YD; Warmus JS; Taylor C
    Bioorg Med Chem Lett; 2009 Feb; 19(3):665-9. PubMed ID: 19121937
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Design and synthesis of 2-amino-pyrazolopyridines as Polo-like kinase 1 inhibitors.
    Fucini RV; Hanan EJ; Romanowski MJ; Elling RA; Lew W; Barr KJ; Zhu J; Yoburn JC; Liu Y; Fahr BT; Fan J; Lu Y; Pham P; Choong IC; VanderPorten EC; Bui M; Purkey HE; Evanchik MJ; Yang W
    Bioorg Med Chem Lett; 2008 Oct; 18(20):5648-52. PubMed ID: 18793847
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Exploring the structure requirement for PKCθ inhibitory activity of pyridinecarbonitrile derivatives: an in silico analysis.
    Li Y; Hao M; Ren H; Zhang S; Wang X; Ma M; Li G; Yang L
    J Mol Graph Model; 2012 Apr; 34():76-88. PubMed ID: 22306416
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Knowledge-based design of 7-azaindoles as selective B-Raf inhibitors.
    Tang J; Hamajima T; Nakano M; Sato H; Dickerson SH; Lackey KE
    Bioorg Med Chem Lett; 2008 Aug; 18(16):4610-4. PubMed ID: 18662874
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discovery of a potent and selective c-Kit inhibitor for the treatment of inflammatory diseases.
    Chen N; Bürli RW; Neira S; Hungate R; Zhang D; Yu V; Nguyen Y; Tudor Y; Plant M; Flynn S; Meagher KL; Lee MR; Zhang X; Itano A; Schrag M; Xu Y; Ng GY; Hu E
    Bioorg Med Chem Lett; 2008 Jul; 18(14):4137-41. PubMed ID: 18554909
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synthesis and SAR of 2-phenoxypyridines as novel c-Jun N-terminal kinase inhibitors.
    Song X; Chen W; Lin L; Ruiz CH; Cameron MD; Duckett DR; Kamenecka TM
    Bioorg Med Chem Lett; 2011 Dec; 21(23):7072-5. PubMed ID: 22004719
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discovery and characterization of the N-phenyl-N'-naphthylurea class of p38 kinase inhibitors.
    Cirillo PF; Hickey ER; Moss N; Breitfelder S; Betageri R; Fadra T; Gaenzler F; Gilmore T; Goldberg DR; Kamhi V; Kirrane T; Kroe RR; Madwed J; Moriak M; Netherton M; Pargellis CA; Patel UR; Qian KC; Sharma R; Sun S; Swinamer A; Torcellini C; Takahashi H; Tsang M; Xiong Z
    Bioorg Med Chem Lett; 2009 May; 19(9):2386-91. PubMed ID: 19356929
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Structure-based design of novel 2-amino-6-phenyl-pyrimido[5',4':5,6]pyrimido[1,2-a]benzimidazol-5(6H)-ones as potent and orally active inhibitors of lymphocyte specific kinase (Lck): synthesis, SAR, and in vivo anti-inflammatory activity.
    Martin MW; Newcomb J; Nunes JJ; Boucher C; Chai L; Epstein LF; Faust T; Flores S; Gallant P; Gore A; Gu Y; Hsieh F; Huang X; Kim JL; Middleton S; Morgenstern K; Oliveira-dos-Santos A; Patel VF; Powers D; Rose P; Tudor Y; Turci SM; Welcher AA; Zack D; Zhao H; Zhu L; Zhu X; Ghiron C; Ermann M; Johnston D; Saluste CG
    J Med Chem; 2008 Mar; 51(6):1637-48. PubMed ID: 18278858
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discovery of a novel and potent series of thieno[3,2-b]pyridine-based inhibitors of c-Met and VEGFR2 tyrosine kinases.
    Claridge S; Raeppel F; Granger MC; Bernstein N; Saavedra O; Zhan L; Llewellyn D; Wahhab A; Deziel R; Rahil J; Beaulieu N; Nguyen H; Dupont I; Barsalou A; Beaulieu C; Chute I; Gravel S; Robert MF; Lefebvre S; Dubay M; Pascal R; Gillespie J; Jin Z; Wang J; Besterman JM; MacLeod AR; Vaisburg A
    Bioorg Med Chem Lett; 2008 May; 18(9):2793-8. PubMed ID: 18434145
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discovery of imidazole vinyl pyrimidines as a novel class of kinase inhibitors which inhibit Tie-2 and are orally bioavailable.
    Buttar D; Edge M; Emery SC; Fitzek M; Forder C; Griffen A; Hayter B; Hayward CF; Hopcroft PJ; Luke RW; Page K; Stawpert J; Wright A
    Bioorg Med Chem Lett; 2008 Aug; 18(16):4723-6. PubMed ID: 18676144
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cell division cycle 7 kinase inhibitors: 1H-pyrrolo[2,3-b]pyridines, synthesis and structure-activity relationships.
    Ermoli A; Bargiotti A; Brasca MG; Ciavolella A; Colombo N; Fachin G; Isacchi A; Menichincheri M; Molinari A; Montagnoli A; Pillan A; Rainoldi S; Sirtori FR; Sola F; Thieffine S; Tibolla M; Valsasina B; Volpi D; Santocanale C; Vanotti E
    J Med Chem; 2009 Jul; 52(14):4380-90. PubMed ID: 19555113
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synthesis of 3,5-bis(2-indolyl)pyridine and 3-[(2-indolyl)-5-phenyl]pyridine derivatives as CDK inhibitors and cytotoxic agents.
    Jacquemard U; Dias N; Lansiaux A; Bailly C; Logé C; Robert JM; Lozach O; Meijer L; Mérour JY; Routier S
    Bioorg Med Chem; 2008 May; 16(9):4932-53. PubMed ID: 18439832
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Potent 2'-aminoanilide inhibitors of cFMS as potential anti-inflammatory agents.
    Patch RJ; Brandt BM; Asgari D; Baindur N; Chadha NK; Georgiadis T; Cheung WS; Petrounia IP; Donatelli RR; Chaikin MA; Player MR
    Bioorg Med Chem Lett; 2007 Nov; 17(22):6070-4. PubMed ID: 17904845
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Discovery and optimization of thieno[2,3-d]pyrimidines as B-Raf inhibitors.
    Packard GK; Papa P; Riggs JR; Erdman P; Tehrani L; Robinson D; Harris R; Shevlin G; Perrin-Ninkovic S; Hilgraf R; McCarrick MA; Tran T; Fleming Y; Bai A; Richardson S; Katz J; Tang Y; Leisten J; Moghaddam M; Cathers B; Zhu D; Sakata S
    Bioorg Med Chem Lett; 2012 Jan; 22(1):747-52. PubMed ID: 22137342
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hit-to-lead studies on benzimidazole inhibitors of ITK: discovery of a novel class of kinase inhibitors.
    Snow RJ; Abeywardane A; Campbell S; Lord J; Kashem MA; Khine HH; King J; Kowalski JA; Pullen SS; Roma T; Roth GP; Sarko CR; Wilson NS; Winters MP; Wolak JP; Cywin CL
    Bioorg Med Chem Lett; 2007 Jul; 17(13):3660-5. PubMed ID: 17499505
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 2-(6-Phenyl-1H-indazol-3-yl)-1H-benzo[d]imidazoles: design and synthesis of a potent and isoform selective PKC-zeta inhibitor.
    Trujillo JI; Kiefer JR; Huang W; Thorarensen A; Xing L; Caspers NL; Day JE; Mathis KJ; Kretzmer KK; Reitz BA; Weinberg RA; Stegeman RA; Wrightstone A; Christine L; Compton R; Li X
    Bioorg Med Chem Lett; 2009 Feb; 19(3):908-11. PubMed ID: 19097791
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A three-step protocol for lead optimization: quick identification of key conformational features and functional groups in the SAR studies of non-ATP competitive MK2 (MAPKAPK2) inhibitors.
    Huang X; Zhu X; Chen X; Zhou W; Xiao D; Degrado S; Aslanian R; Fossetta J; Lundell D; Tian F; Trivedi P; Palani A
    Bioorg Med Chem Lett; 2012 Jan; 22(1):65-70. PubMed ID: 22169260
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Scaffold oriented synthesis. Part 2: Design, synthesis and biological evaluation of pyrimido-diazepines as receptor tyrosine kinase inhibitors.
    Gracias V; Ji Z; Akritopoulou-Zanze I; Abad-Zapatero C; Huth JR; Song D; Hajduk PJ; Johnson EF; Glaser KB; Marcotte PA; Pease L; Soni NB; Stewart KD; Davidsen SK; Michaelides MR; Djuric SW
    Bioorg Med Chem Lett; 2008 Apr; 18(8):2691-5. PubMed ID: 18362070
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synthesis and SAR studies of potent imidazopyridine anticoccidial agents.
    Liang GB; Qian X; Feng D; Fisher M; Brown CM; Gurnett A; Leavitt PS; Liberator PA; Misura AS; Tamas T; Schmatz DM; Wyvratt M; Biftu T
    Bioorg Med Chem Lett; 2007 Jul; 17(13):3558-61. PubMed ID: 17475489
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synthesis and structure-activity relationship of 3,4'-bispyridinylethylenes: discovery of a potent 3-isoquinolinylpyridine inhibitor of protein kinase B (PKB/Akt) for the treatment of cancer.
    Li Q; Woods KW; Thomas S; Zhu GD; Packard G; Fisher J; Li T; Gong J; Dinges J; Song X; Abrams J; Luo Y; Johnson EF; Shi Y; Liu X; Klinghofer V; Des Jong R; Oltersdorf T; Stoll VS; Jakob CG; Rosenberg SH; Giranda VL
    Bioorg Med Chem Lett; 2006 Apr; 16(7):2000-7. PubMed ID: 16413780
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.